Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Walter, Roland B.; Othus, Megan; Burnett, Alan Kenneth; Löwenberg, Bob; Kantarjian, Hagop M.; Ossenkoppele, Gert J.; Hills, Robert Kerrin; Montfort, Kees G. M. van; Ravandi, Farhad; Evans, Anna; Pierce, Sherry; Appelbaum, Frederick R.; Estey, Elihu H.

doi:10.1182/blood-2012-10-462440

Cited by 111 publications

(81 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the subcategories of AML, not otherwise specified (NOS) lack prognostic significance when cases are classified based on NPM1 mutation and CEBPA biallelic mutation status, 101 the CAC agreed to keep the AML, NOS subcategories with only a single change: the subcategory of acute erythroid leukemia, erythroid/myeloid type (previously defined as a case with $50% BM erythroid precursors and $20% myeloblasts among nonerythroid cells) has been removed from the AML category. In the new classification, myeloblasts are always counted as a percentage of total marrow cells and the majority of (should be specifically excluded in cases with eosinophilia)…”

Section: Aml Not Otherwise Specifiedmentioning

confidence: 99%

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber

Orazi

Hasserjian

et al. 2016

Blood

8,092

7,810

View full text Add to dashboard Cite

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

show abstract

Section: Aml Not Otherwise Specifiedmentioning

confidence: 99%

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber

Orazi

Hasserjian

et al. 2016

Blood

8,092

7,810

View full text Add to dashboard Cite

show abstract

“…A distinct clinical and biological subtype of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL) was previously classified as AML-M3 in the older French-AmericanBritish (FAB) classification system, (1,2) and then as APL with t(15;17)(q24.1;q21.1) and promyelocytic leukaemia-retinoic acid receptor alpha (PML-RARA) by World Health Organization. (3) APL makes up nearly 5%-8% of cases of AML.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre

Karim¹,

Shaikh²,

Adil³

et al. 2014

smedj

View full text Add to dashboard Cite

“…AML is divided into subgroups that are distinguished by the morphology of the leukemia cells, specific chromosomal abnormalities, gene rearrangement patterns, and different clinical courses and response to therapy (Douer, 2003). AML is subdivided based on morphologic criteria by the French-AmericanBritish (FAB) classification (Walter et al, 2013). FAB group has classified AML cases into eight subgroups (M0-M7) (Ziaei, 2004).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Allahyari

Tajeri²,

Sadeghi³

2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

In all patients, 76% had fever and 50% consumed amphotericin. T(15;17)(q22;q21) had the most prevalence (37.7%) compared to other forms. Out of 92 patients, O+(30.4%) was the most common blood group and AML-M5 (28.3%) the most common subtype. There was a significant difference in survival based on WBC and consumption of amphotericin B (P<0.05). Conclusions: WBC level, fever and consumption of amphotericin B proved to be factors for survival of AML patients. The mean age for patients in Iran is lower than other areas in the World and also survival in this study was higher than in other studies.

show abstract

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Abstract: • The FAB type (ie, M0-M7) does not provide prognostic information for cases of "AML, NOS" in the 2008 WHO classification.

Cited by 111 publications

References 15 publications

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Contact Info

Product

Resources

About